{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:56:48Z","timestamp":1787021808781,"version":"build-2736575974"},"update-to":[{"DOI":"10.1371\/journal.pmed.1005047","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000}}],"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001839","name":"University Grants Committee","doi-asserted-by":"publisher","award":["R7007-22"],"award-info":[{"award-number":["R7007-22"]}],"id":[{"id":"10.13039\/501100001839","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment-resistant depression (TRD), defined as failure to respond to at least two adequately administered antidepressant (AD) regimens, imposes major clinical and economic burdens. Esketamine nasal spray offers rapid antidepressant clinical effects, yet previous evaluations compared it only with unrealistic comparators such as AD monotherapy. This study assessed the cost-effectiveness of esketamine versus multiple alternative third-line strategies for TRD from the Hong Kong healthcare payer\u2019s perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>A Markov cohort model simulated adults with TRD in Hong Kong over 5 years with 4-week cycles. The model compared esketamine plus AD with six alternative third-line treatment strategies: combination therapy (AD plus AD), augmentation therapy (AD plus antipsychotic or lithium), psychotherapy alone, psychotherapy plus AD, repetitive transcranial magnetic stimulation (rTMS) plus AD, and electroconvulsive therapy (ECT) plus AD. Primary outcomes were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) under a US$50,000\/QALY willingness-to-pay (WTP) threshold. Deterministic and probabilistic sensitivity analyses and scenario analyses were conducted, focusing on alternative esketamine dosing, delivery strategies, and comparisons with other treatment options to assess the robustness of the results. In base-case analysis, esketamine was not cost-effective versus augmentation, combination, psychotherapy, or psychotherapy plus AD with ICERs ranging from US$134,127 to US$312,750 per QALY but was more cost-effective than rTMS (dominated) and ECT (ICER: US$322,407\/QALY). Combination therapy was the most cost-effective among all strategies evaluated. The main limitation of this study is the reliance on indirect comparisons and assumptions derived from heterogeneous clinical trial populations, which may not fully reflect real-world patient characteristics and treatment pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Esketamine appeared more cost-effective than rTMS and ECT, but not cost-effective compared with other commonly used third-line treatment strategies for TRD. These findings suggest that cost-effectiveness evidence may help inform more context-sensitive treatment sequencing strategies beyond conventional line-of-therapy frameworks. Policy approaches such as price negotiation, optimized service delivery, and alternative dosing strategies may improve the value of esketamine for TRD management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1005047","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:48:02Z","timestamp":1776361682000},"page":"e1005047","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9822-3397","authenticated-orcid":true,"given":"Yifan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1124-0398","authenticated-orcid":true,"given":"Vivien Kin Yi","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-8255","authenticated-orcid":true,"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-1575","authenticated-orcid":true,"given":"Franco Wing Tak","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hei Hang Edmund","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Makram","family":"Bishai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-0096","authenticated-orcid":true,"given":"Dawn","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":true,"given":"Esther Wai Yin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Sau Man","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-7808","authenticated-orcid":true,"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"11","key":"pmed.1005047.ref001","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"AJ Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"pmed.1005047.ref002","first-page":"100426","article-title":"Mortality-causing mechanisms and healthcare resource utilisation of treatment-resistant depression: a six-year population-based cohort study","volume":"22","author":"VK Chan","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"pmed.1005047.ref003","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41398-023-02383-9","article-title":"Treatment-resistant depression and risk of autoimmune diseases: evidence from a population-based cohort and nested case-control study","volume":"13","author":"VKY Chan","year":"2023","journal-title":"Transl Psychiatry"},{"key":"pmed.1005047.ref004","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 2010 [cited 1 September 2022]. Available from: https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf"},{"key":"pmed.1005047.ref005","unstructured":"American Psychological Association. APA clinical practice guideline for the treatment of depression across three age cohorts [cited 2023 July 31]. Available from: https:\/\/www.apa.org\/depression-guideline"},{"key":"pmed.1005047.ref006","unstructured":"U.S. Food and Drug Administration. NDA 211243 approval letter for Spravato (esketamine) nasal spray. Silver Spring (MD): FDA; 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/211243Orig1s000ltr.pdf"},{"key":"pmed.1005047.ref007","unstructured":"Agency EM. Spravato [cited June 2, 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spravato"},{"key":"pmed.1005047.ref008","unstructured":"Companies JP. Spravato\u00ae (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression [cited 2025 June 2]. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression"},{"key":"pmed.1005047.ref009","doi-asserted-by":"crossref","first-page":"2042098620937899","DOI":"10.1177\/2042098620937899","article-title":"Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review","volume":"11","author":"MS Salahudeen","year":"2020","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"pmed.1005047.ref010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: a review","volume":"2","author":"M Yavi","year":"2022","journal-title":"Discov Ment Health"},{"issue":"6","key":"pmed.1005047.ref011","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"V Popova","year":"2019","journal-title":"Am J Psychiatry"},{"issue":"9","key":"pmed.1005047.ref012","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"EJ Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"pmed.1005047.ref013","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ps.201900625","article-title":"Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States","volume":"71","author":"EL Ross","year":"2020","journal-title":"Psychiatr Serv"},{"issue":"1","key":"pmed.1005047.ref014","first-page":"16","article-title":"The effectiveness and value of esketamine for the management of treatment-resistant depression","volume":"26","author":"F Agboola","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"pmed.1005047.ref015","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jad.2022.09.083","article-title":"Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates","volume":"319","author":"M Brendle","year":"2022","journal-title":"J Affect Disord"},{"issue":"1","key":"pmed.1005047.ref016","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/s12888-021-03601-8","article-title":"Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression","volume":"21","author":"K Degerlund Maldi","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"2","key":"pmed.1005047.ref017","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40273-022-01220-z","article-title":"Cost-utility analysis of esketamine for patients with treatment-resistant depression in Italy","volume":"41","author":"C Rognoni","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"pmed.1005047.ref018","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH common drug review: pharmacoeconomic report: esketamine hydrochloride (Spravato). 2021. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572204\/"},{"key":"pmed.1005047.ref019","article-title":"Esketamine nasal spray for treatment-resistant depression.","author":"National Institute for Health and Care Excellence.","year":"2022","journal-title":"London: NICE"},{"issue":"1","key":"pmed.1005047.ref020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"D Husereau","year":"2022","journal-title":"Value Health"},{"key":"pmed.1005047.ref021","first-page":"51","article-title":"Healthcare service in Hong Kong and its challenges.","volume":"4","author":"V Schoeb","year":"2016","journal-title":"China Perspect"},{"key":"pmed.1005047.ref022","article-title":"Thematic Household Survey Report No. 58: Health Status of Hong Kong Residents.","author":"Census and Statistics Department.","year":"2015","journal-title":"Hong Kong: Census and Statistics Department"},{"key":"pmed.1005047.ref023","first-page":"101026","article-title":"Projecting the 10-year costs of care and mortality burden of depression until 2032: a Markov modelling study developed from real-world data","volume":"45","author":"VKY Chan","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"pmed.1005047.ref024","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006"},{"issue":"10","key":"pmed.1005047.ref025","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)","volume":"22","author":"M Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"pmed.1005047.ref026","article-title":"Pharmacological interventions for treatment-resistant depression in adults","volume":"12","author":"P Davies","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"pmed.1005047.ref027","article-title":"Psychological therapies for treatment-resistant depression in adults","volume":"5","author":"S Ijaz","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pmed.1005047.ref028","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1192\/bjp.2020.198","article-title":"Psychological interventions as an alternative and add-on to antidepressant medication to prevent depressive relapse: systematic review and meta-analysis","volume":"219","author":"JJF Breedvelt","year":"2021","journal-title":"Br J Psychiatry"},{"issue":"2","key":"pmed.1005047.ref029","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.brs.2023.01.1680","article-title":"Repetitive transcranial magnetic stimulation for preventing relapse in antidepressant treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Y Matsuda","year":"2023","journal-title":"Brain Stimul"},{"issue":"3","key":"pmed.1005047.ref030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1503\/jpn.180056","article-title":"Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression: a meta-analysis of randomized controlled trials over 2 decades","volume":"44","author":"S Sehatzadeh","year":"2019","journal-title":"J Psychiatry Neurosci"},{"issue":"3","key":"pmed.1005047.ref031","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1017\/S003329171800199X","article-title":"Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression","volume":"49","author":"S van Bronswijk","year":"2019","journal-title":"Psychol Med"},{"issue":"6","key":"pmed.1005047.ref032","first-page":"853","article-title":"Meta-analysis of the efficacy and safety of MECT combined with SSRIs in the treatment of treatment-resistant depression","volume":"39","author":"LG Zhou","year":"2014","journal-title":"J Chongqing Med Univ"},{"issue":"26","key":"pmed.1005047.ref033","article-title":"Treatment of adults with treatment-resistant depression: electroconvulsive therapy plus antidepressant or electroconvulsive therapy alone? Evidence from an indirect comparison meta-analysis","volume":"94","author":"G-M Song","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"pmed.1005047.ref034","article-title":"Effectiveness of electroconvulsive therapy for preventing relapse and recurrence of depression in adults with major depressive disorder: an updated meta-analysis of randomized clinical trials","volume":"15","author":"H Dar","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"pmed.1005047.ref035","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.14r09204","article-title":"Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis","volume":"76","author":"X Zhou","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"63","key":"pmed.1005047.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22630","article-title":"Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT","volume":"22","author":"D Kessler","year":"2018","journal-title":"Health Technol Assess"},{"key":"pmed.1005047.ref037","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"176","author":"S Durgam","year":"2016","journal-title":"Schizophr Res"},{"issue":"4","key":"pmed.1005047.ref038","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study","volume":"70","author":"M Bauer","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"pmed.1005047.ref039","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.4088\/JCP.v68n0714","article-title":"Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study","volume":"68","author":"DL Dunner","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"pmed.1005047.ref040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"RC Shelton","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"7","key":"pmed.1005047.ref041","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study","volume":"13","author":"N El-Khalili","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"pmed.1005047.ref042","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1176\/appi.ajp.2015.14101251","article-title":"Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study","volume":"172","author":"GI Papakostas","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"9","key":"pmed.1005047.ref043","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/14656566.8.9.1211","article-title":"A preclinical and clinical rationale for quetiapine in mood syndromes","volume":"8","author":"RS McIntyre","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"pmed.1005047.ref044","unstructured":"Authority H. List of private services [cited 2025 April 30]. Available from: https:\/\/www3.ha.org.hk\/fnc\/Pathology.aspx?lang=ENG"},{"key":"pmed.1005047.ref045","unstructured":"Authority H. Revision to list of charges: Public charges for non-eligible persons under chapter 113 [cited 2025 April 30]. Available from: https:\/\/www.ha.org.hk\/haho\/ho\/cs\/238767_en.pdf"},{"key":"pmed.1005047.ref046","unstructured":"Companies JP. Dosage and administration of Spravato: duration of therapy [cited 2025 April 30]. Available from: https:\/\/www.jnjmedicalconnect.com\/products\/spravato\/medical-content\/dosage-and-administration-of-spravato-duration-of-therapy"},{"key":"pmed.1005047.ref047","unstructured":"PsychDB. Cognitive Behavioral Therapy (CBT) [cited 2025 April 30]. Available from: https:\/\/www.psychdb.com\/psychotherapy\/cbt"},{"key":"pmed.1005047.ref048","unstructured":"Peprah K, Arg\u00e1ez C. Dialectical behavioral therapy for adults with mental illness: a review of clinical effectiveness and guidelines. 2017. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK525629\/"},{"key":"pmed.1005047.ref049","unstructured":"Clinic C. Interpersonal Psychotherapy (IPT) [cited 2025 April 30]. Available from: https:\/\/my.clevelandclinic.org\/health\/treatments\/interpersonal-psychotherapy-ipt"},{"issue":"1","key":"pmed.1005047.ref050","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16cs10905","article-title":"Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression","volume":"79","author":"SM McClintock","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"pmed.1005047.ref051","unstructured":"Psychiatrists RA. Electroconvulsive Therapy (ECT) [cited 2025 April 30]. Available from: https:\/\/www.ranzcp.org\/clinical-guidelines-publications\/clinical-guidelines-publications-library\/electroconvulsive-therapy-ect"},{"key":"pmed.1005047.ref052","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-2-20","article-title":"Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder","volume":"2","author":"C Sapin","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"pmed.1005047.ref053","unstructured":"Bank W. GDP per capita (current US$) \u2013 Hong Kong SAR, China) [cited 2025 January 7]. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=HK"},{"issue":"10","key":"pmed.1005047.ref054","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70153","article-title":"Cost-effectiveness analysis of nirsevimab for respiratory syncytial virus disease prevention in newborns of Hong Kong","volume":"19","author":"Y Wang","year":"2025","journal-title":"Influenza Other Respir Viruses"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1005047","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:49:03Z","timestamp":1777312143000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005047"}},"subtitle":[],"editor":[{"given":"Alexander C.","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1005047","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}